01:28:38 Europe / Stockholm

Prenumeration

2023-03-23 10:26:00

Q-linea is in the early stage of its targeted European launch strategy. The strong point is that Q-linea has developed a product ready for clinical use with positive initial feedback. The main go-to-market challenge is that it could take a bit longer to introduce ASTar in Europe without an international partner. The European market will require supporting clinical studies, including positive peer-to-peer review, before accepting rapid AST as a larger part of the standard of care.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/